AVENIO ctDNA Expanded Kit V2

Material Number: Select a variation

Next-generation sequencing (NGS) liquid biopsy tumor profiling assay for identifying genomic aberrations in solid tumors containing 77 genes.

The AVENIO ctDNA Expanded Kit V2 is a next-generation sequencing (NGS) liquid biopsy research assay with a 77 gene panel containing genes in U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers. It is a pan-cancer assay that’s specially optimized for lung cancer and colorectal cancer (CRC) research.

Features and Benefits

  • Contains genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers
  • All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
  • Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
  • Includes reagents, bioinformatics and software
  • Streamlined, end-to-end research workflow from extraction to analysis and reporting in five days


  • Panel size: 192 kb

  • Sample size: 4 ml of plasma

  • cfDNA input: 10-50 ng

  • Reactions per kit: 16

  • Turn-around time: 5 days from extraction to results


Box # Sub-kit name
1 AVENIO cfDNA Isolation Kit V2
2 AVENIO Library Prep Kit V2
3 AVENIO cfDNA Enrichment Kit V2
4 AVENIO cfDNA Expanded Panel V2
5 AVENIO Post-Hybridization Kit V2

Exceptional Performance3

View full genes list here


  1. National Comprehensive Cancer Network. Accessed August 2, 2023.
  2. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine. 2014;20(5):548–554 doi:10.1038/nm.3519
  3. Data on file with Roche.

Product variations

Material Number Name Price
09733779001 AVENIO ctDNA Expanded Kit V2 - 16 rxn Log in or register to see the price

Other products in this category